Effects of elexacaftor–tezacaftor–ivacaftor discontinuation in cystic fibrosis - 29/11/22
Doi : 10.1016/j.resmer.2022.100972
Georgia Mitropoulou a, b, ⁎ 
, Zisis Balmpouzis a, b, Jérôme Plojoux c, Jennifer Dotta-Celio d, Alain Sauty a, e, 1, Angela Koutsokera a, b, 1
, Zisis Balmpouzis a, b, Jérôme Plojoux c, Jennifer Dotta-Celio d, Alain Sauty a, e, 1, Angela Koutsokera a, b, 1 a Adult Cystic Fibrosis and CFTR-related disorders Center, Division of Pulmonology, Dept of Medicine, Lausanne University Hospital and University of Lausanne, Switzerland
b Lung Transplant Center, Division of Pulmonology, Dept of Medicine, Lausanne University Hospital and University of Lausanne, Switzerland
c Division of Pulmonology, Geneva University Hospitals, Switzerland
d Community Pharmacy, Centre for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland
e Division of Pulmonology, Neuchâtel Hospital Network, Neuchâtel, Switzerland
⁎Corresponding author at: Division of Pulmonology, Lausanne University Hospital, Rue du Bugnon 46, 1011 Lausanne, Switzerland.Division of Pulmonology, Lausanne University HospitalRue du Bugnon 46Lausanne1011Switzerland
Keywords : Elexacaftor–tezacaftor–ivacaftor, Withdrawal, Adherence, Bronchiolitis
Le texte complet de cet article est disponible en PDF.
Plan
© 2022
SPLF and Elsevier Masson SAS. Tous droits réservés.
Vol 82
Article 100972- novembre 2022 Retour au numéro
Article précédent
- Familial pleuroparenchymal fibroelastosis: an entity to be recognized
- Yoshiaki Kinoshita, Takuhide Utsunomiya, Yohei Koide, Kenji Wada, Yusuke Ueda, Yuji Yoshida, Hisako Kushima, Hiroshi Ishii, Takuto Miyamura, Miwako Matsuzaki
- Letter to Hitomi Tomohara-Ichishima et al
- Kanji Yamada
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?